180 Life Sciences director receives 181,422 options; exercisability pending shareholder approval
Rhea-AI Filing Summary
Stephen H. Shoemaker, a director of 180 Life Sciences Corp. (ticker shown as ATNF), reported a sale of 132,439 common shares and the receipt of a grant of 181,422 non-qualified stock options. The options carry an exercise price of $3.01 and were granted in consideration for services as a director; they vested immediately but are not exercisable until stockholder approval of the issuer's 2025 Second Supplemental Option Plan is received. If that approval is not obtained before August 8, 2026, the options will be cancelled. Following the reported transactions, the reporting person beneficially owns 181,422 option-based shares (direct). The filing discloses both an immediate disposal of existing common stock and a conditional, potentially dilutive option award tied to shareholder approval.
Positive
- Options were granted as director compensation in consideration for services rendered and agreed to be rendered, an explicit non-cash form of compensation.
- The options vested immediately, ensuring the reporting person has earned the award under the plan's terms.
Negative
- Reported disposition of 132,439 common shares, indicating an insider sale that reduces the reporting person’s direct common-stock holdings.
- Options are not exercisable until shareholder approval of the 2025 Second Supplemental Option Plan; they will be cancelled if approval is not received by August 8, 2026.
- Grant creates potential dilution of 181,422 shares if the options become exercisable and are exercised.
Insights
TL;DR: Insider sold 132,439 shares and received 181,422 options at $3.01 that vest now but await shareholder approval to be exercisable.
The transaction shows two concurrent developments: an outright disposition of common stock and a sizeable option grant to a director. The option grant is explicitly for services and vests immediately, which creates potential dilution of 181,422 shares if exercised. However, exercisability is conditional on shareholder approval of the supplemental plan, with a backstop cancellation date of August 8, 2026, limiting immediate conversion risk. Without additional capital structure details, the exact dilution impact on outstanding shares cannot be quantified from this form alone.
TL;DR: Director compensation was granted with immediate vesting but requires shareholder approval to exercise, creating a conditional award with governance oversight.
The filing confirms the options were issued in consideration for director services and vested immediately, but they remain non-exercisable pending stockholder approval of the 2025 Second Supplemental Option Plan. The requirement for shareholder approval and the explicit cancellation clause if approval is not obtained by August 8, 2026 are governance controls that limit automatic benefit from the grant. The immediate vesting combined with conditional exercisability is a hybrid treatment that should be evaluated in the context of the company’s broader equity-compensation policies.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Non-Qualified Stock Option (right to buy) | 181,422 | $0.00 | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The options were granted under the 2025 Second Supplemental Option Plan of the Issuer. The options vested immediately, but are not exercisable until stockholder approval of the 2025 Second Supplemental Option Plan is received. If stockholder approval is not received prior to August 8, 2026, the options will be cancelled. Issued to the Reporting Person in consideration for services rendered and agreed to be rendered to the Issuer as a director of the Issuer.
